67% of MWL Patients Seek Aesthetic Care; 60% Source GLP-1 from Aesthetic Providers
Allergan Aesthetics data shows 67% of MWL patients shift goals toward appearance, with 47% benefiting most from hyaluronic acid fillers and 60% obtaining GLP-1 drugs from providers offering aesthetic treatments, up from 49% in late 2024. AbbVie also presented at TD Cowen’s 46th Health Care Conference without delivering new guidance.
1. Medical Weight Loss Patients Shift Aesthetic Priorities
Allergan Aesthetics reports that 67% of patients undergoing medical weight loss now prioritize appearance improvements, not just weight reduction. Healthcare providers note 47% of these patients benefit most from hyaluronic acid injectable fillers to address post-weight-loss facial volume loss.
2. Growth in GLP-1 and Aesthetic Service Bundling
Sixty percent of consumers receiving GLP-1 medications now obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024. This trend underscores increasing consumer demand for combined weight loss and aesthetic care under one roof.
3. AbbVie Presentation at TD Cowen Conference
AbbVie presented at the TD Cowen 46th Annual Health Care Conference but did not provide new financial guidance or unveil major product updates. The session focused on strategic outlooks and reaffirmed AbbVie’s commitment to expanding its aesthetics portfolio.